Alumis Inc. (ALMS) Stock Competitors & Peer Comparison

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, VRTX has a market cap of 132.5B. Regarding current trading prices, ALMS is priced at $29.27, while VRTX trades at $522.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas VRTX's P/E ratio is 27.74. In terms of profitability, ALMS's ROE is -0.55%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ALMS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check VRTX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ALMS is priced at $29.27, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ALMS's ROE is -0.55%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ALMS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check VRNA's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, REGN has a market cap of 69.7B. Regarding current trading prices, ALMS is priced at $29.27, while REGN trades at $676.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas REGN's P/E ratio is 14.82. In terms of profitability, ALMS's ROE is -0.55%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ALMS is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check REGN's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ARGX has a market cap of 56.9B. Regarding current trading prices, ALMS is priced at $29.27, while ARGX trades at $919.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ARGX's P/E ratio is 83.03. In terms of profitability, ALMS's ROE is -0.55%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, ALMS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ARGX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ALMS is priced at $29.27, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ALMS's ROE is -0.55%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ALMS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check SGEN's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ALNY has a market cap of 42.9B. Regarding current trading prices, ALMS is priced at $29.27, while ALNY trades at $321.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ALNY's P/E ratio is 57.94. In terms of profitability, ALMS's ROE is -0.55%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ALMS is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ALNY's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, RVMDW has a market cap of 41B. Regarding current trading prices, ALMS is priced at $29.27, while RVMDW trades at $9.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas RVMDW's P/E ratio is -2.35. In terms of profitability, ALMS's ROE is -0.55%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ALMS is more volatile compared to RVMDW. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check RVMDW's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, RVMD has a market cap of 40.5B. Regarding current trading prices, ALMS is priced at $29.27, while RVMD trades at $190.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas RVMD's P/E ratio is -26.94. In terms of profitability, ALMS's ROE is -0.55%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ALMS is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check RVMD's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ONC has a market cap of 33B. Regarding current trading prices, ALMS is priced at $29.27, while ONC trades at $308.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ONC's P/E ratio is 69.12. In terms of profitability, ALMS's ROE is -0.55%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ALMS is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ONC's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, MRNA has a market cap of 31.7B. Regarding current trading prices, ALMS is priced at $29.27, while MRNA trades at $79.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas MRNA's P/E ratio is -9.79. In terms of profitability, ALMS's ROE is -0.55%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ALMS is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check MRNA's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ROIV has a market cap of 26.1B. Regarding current trading prices, ALMS is priced at $29.27, while ROIV trades at $36.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ROIV's P/E ratio is -40.29. In terms of profitability, ALMS's ROE is -0.55%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ALMS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ROIV's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, INSM has a market cap of 24.5B. Regarding current trading prices, ALMS is priced at $29.27, while INSM trades at $112.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas INSM's P/E ratio is -19.62. In terms of profitability, ALMS's ROE is -0.55%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ALMS is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check INSM's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, UTHR has a market cap of 23.9B. Regarding current trading prices, ALMS is priced at $29.27, while UTHR trades at $563.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas UTHR's P/E ratio is 20.81. In terms of profitability, ALMS's ROE is -0.55%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ALMS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check UTHR's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, BNTX has a market cap of 23.8B. Regarding current trading prices, ALMS is priced at $29.27, while BNTX trades at $94.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas BNTX's P/E ratio is -20.41. In terms of profitability, ALMS's ROE is -0.55%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ALMS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check BNTX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, INCY has a market cap of 23.6B. Regarding current trading prices, ALMS is priced at $29.27, while INCY trades at $118.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas INCY's P/E ratio is 15.87. In terms of profitability, ALMS's ROE is -0.55%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ALMS is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check INCY's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ALMS is priced at $29.27, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ALMS's ROE is -0.55%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ALMS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check BGNE's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ALMS is priced at $29.27, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ALMS's ROE is -0.55%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ALMS is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check DNA-WT's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, GMAB has a market cap of 17.9B. Regarding current trading prices, ALMS is priced at $29.27, while GMAB trades at $29.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas GMAB's P/E ratio is 20.99. In terms of profitability, ALMS's ROE is -0.55%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ALMS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check GMAB's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, NBIX has a market cap of 17.8B. Regarding current trading prices, ALMS is priced at $29.27, while NBIX trades at $177.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas NBIX's P/E ratio is 25.65. In terms of profitability, ALMS's ROE is -0.55%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ALMS is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check NBIX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ASND has a market cap of 16.6B. Regarding current trading prices, ALMS is priced at $29.27, while ASND trades at $266.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ASND's P/E ratio is -110.32. In terms of profitability, ALMS's ROE is -0.55%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ALMS is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ASND's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, JAZZ has a market cap of 15.6B. Regarding current trading prices, ALMS is priced at $29.27, while JAZZ trades at $247.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas JAZZ's P/E ratio is 19.26. In terms of profitability, ALMS's ROE is -0.55%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ALMS is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check JAZZ's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, BBIO has a market cap of 15.3B. Regarding current trading prices, ALMS is priced at $29.27, while BBIO trades at $77.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas BBIO's P/E ratio is -20.83. In terms of profitability, ALMS's ROE is -0.55%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ALMS is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check BBIO's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, EXEL has a market cap of 14.3B. Regarding current trading prices, ALMS is priced at $29.27, while EXEL trades at $57.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas EXEL's P/E ratio is 17.09. In terms of profitability, ALMS's ROE is -0.55%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ALMS is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check EXEL's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, IONS has a market cap of 14.3B. Regarding current trading prices, ALMS is priced at $29.27, while IONS trades at $86.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas IONS's P/E ratio is -50.19. In terms of profitability, ALMS's ROE is -0.55%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ALMS is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check IONS's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, AXSM has a market cap of 12.9B. Regarding current trading prices, ALMS is priced at $29.27, while AXSM trades at $249.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas AXSM's P/E ratio is -65.21. In terms of profitability, ALMS's ROE is -0.55%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ALMS is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check AXSM's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ALMS is priced at $29.27, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ALMS's ROE is -0.55%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ALMS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check KRTX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, MDGL has a market cap of 12.6B. Regarding current trading prices, ALMS is priced at $29.27, while MDGL trades at $545.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas MDGL's P/E ratio is -42.61. In terms of profitability, ALMS's ROE is -0.55%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ALMS is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check MDGL's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, SMMT has a market cap of 12.3B. Regarding current trading prices, ALMS is priced at $29.27, while SMMT trades at $15.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas SMMT's P/E ratio is -9.93. In terms of profitability, ALMS's ROE is -0.55%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ALMS is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check SMMT's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ARWR has a market cap of 12.3B. Regarding current trading prices, ALMS is priced at $29.27, while ARWR trades at $86.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ARWR's P/E ratio is -40.45. In terms of profitability, ALMS's ROE is -0.55%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ALMS is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ARWR's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, BMRN has a market cap of 11.7B. Regarding current trading prices, ALMS is priced at $29.27, while BMRN trades at $60.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas BMRN's P/E ratio is 29.01. In terms of profitability, ALMS's ROE is -0.55%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ALMS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check BMRN's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ALMS is priced at $29.27, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ALMS's ROE is -0.55%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ALMS is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check RNAM's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, TECH has a market cap of 11.1B. Regarding current trading prices, ALMS is priced at $29.27, while TECH trades at $70.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas TECH's P/E ratio is 36.40. In terms of profitability, ALMS's ROE is -0.55%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ALMS is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check TECH's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, KRYS has a market cap of 10.9B. Regarding current trading prices, ALMS is priced at $29.27, while KRYS trades at $368.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas KRYS's P/E ratio is 49.28. In terms of profitability, ALMS's ROE is -0.55%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ALMS is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check KRYS's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CYTK has a market cap of 10.6B. Regarding current trading prices, ALMS is priced at $29.27, while CYTK trades at $85.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CYTK's P/E ratio is -14.68. In terms of profitability, ALMS's ROE is -0.55%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ALMS is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check CYTK's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CORT has a market cap of 10.1B. Regarding current trading prices, ALMS is priced at $29.27, while CORT trades at $94.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CORT's P/E ratio is 268.69. In terms of profitability, ALMS's ROE is -0.55%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ALMS is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check CORT's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, KYMR has a market cap of 9.8B. Regarding current trading prices, ALMS is priced at $29.27, while KYMR trades at $119.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas KYMR's P/E ratio is -33.78. In terms of profitability, ALMS's ROE is -0.55%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ALMS is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check KYMR's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, ALMS is priced at $29.27, while HALO trades at $81.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas HALO's P/E ratio is 17.66. In terms of profitability, ALMS's ROE is -0.55%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ALMS is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check HALO's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ALMS is priced at $29.27, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ALMS's ROE is -0.55%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ALMS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check RXDX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ABVX has a market cap of 9.3B. Regarding current trading prices, ALMS is priced at $29.27, while ABVX trades at $142.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ABVX's P/E ratio is -74.36. In terms of profitability, ALMS's ROE is -0.55%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ALMS is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ABVX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ALKS has a market cap of 9.2B. Regarding current trading prices, ALMS is priced at $29.27, while ALKS trades at $55.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ALKS's P/E ratio is 58.13. In terms of profitability, ALMS's ROE is -0.55%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ALMS is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ALKS's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, IBRX has a market cap of 9.2B. Regarding current trading prices, ALMS is priced at $29.27, while IBRX trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas IBRX's P/E ratio is -27.37. In terms of profitability, ALMS's ROE is -0.55%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ALMS is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check IBRX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ALMS is priced at $29.27, while NUVL trades at $123.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas NUVL's P/E ratio is -21.75. In terms of profitability, ALMS's ROE is -0.55%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ALMS is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check NUVL's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, ALMS is priced at $29.27, while PTGX trades at $140.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas PTGX's P/E ratio is -77.64. In terms of profitability, ALMS's ROE is -0.55%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ALMS is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check PTGX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, TGTX has a market cap of 8.9B. Regarding current trading prices, ALMS is priced at $29.27, while TGTX trades at $58.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas TGTX's P/E ratio is 19.95. In terms of profitability, ALMS's ROE is -0.55%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ALMS is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check TGTX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, ALMS is priced at $29.27, while PCVX trades at $60.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas PCVX's P/E ratio is -8.82. In terms of profitability, ALMS's ROE is -0.55%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ALMS is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check PCVX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ALMS is priced at $29.27, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ALMS's ROE is -0.55%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ALMS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check IMGN's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ALMS is priced at $29.27, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ALMS's ROE is -0.55%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ALMS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check BPMC's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, ALMS is priced at $29.27, while APGE trades at $133.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas APGE's P/E ratio is -30.84. In terms of profitability, ALMS's ROE is -0.55%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ALMS is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check APGE's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, ALMS is priced at $29.27, while IMVT trades at $40.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas IMVT's P/E ratio is -15.01. In terms of profitability, ALMS's ROE is -0.55%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ALMS is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check IMVT's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ALMS is priced at $29.27, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CERE's P/E ratio is -16.47. In terms of profitability, ALMS's ROE is -0.55%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ALMS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check CERE's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, ALMS is priced at $29.27, while RYTM trades at $114.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas RYTM's P/E ratio is -36.57. In terms of profitability, ALMS's ROE is -0.55%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ALMS is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check RYTM's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ALMS is priced at $29.27, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ALMS's ROE is -0.55%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ALMS is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check MTSR's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, PTCT has a market cap of 7.4B. Regarding current trading prices, ALMS is priced at $29.27, while PTCT trades at $89.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas PTCT's P/E ratio is -38.28. In terms of profitability, ALMS's ROE is -0.55%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ALMS is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check PTCT's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, LQDA has a market cap of 7.2B. Regarding current trading prices, ALMS is priced at $29.27, while LQDA trades at $81.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas LQDA's P/E ratio is 580.21. In terms of profitability, ALMS's ROE is -0.55%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ALMS is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check LQDA's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, ALMS is priced at $29.27, while PRAX trades at $323.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas PRAX's P/E ratio is -24.23. In terms of profitability, ALMS's ROE is -0.55%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ALMS is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check PRAX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, COGT has a market cap of 6.8B. Regarding current trading prices, ALMS is priced at $29.27, while COGT trades at $40.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas COGT's P/E ratio is -18.96. In terms of profitability, ALMS's ROE is -0.55%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ALMS is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check COGT's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ALMS is priced at $29.27, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ALMS's ROE is -0.55%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ALMS is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check MRUS's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, SRRK has a market cap of 6.8B. Regarding current trading prices, ALMS is priced at $29.27, while SRRK trades at $56.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas SRRK's P/E ratio is -15.75. In terms of profitability, ALMS's ROE is -0.55%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ALMS is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check SRRK's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ALMS is priced at $29.27, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ALMS's ROE is -0.55%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ALMS is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ACLX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ALMS is priced at $29.27, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas RETA's P/E ratio is -66.29. In terms of profitability, ALMS's ROE is -0.55%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ALMS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check RETA's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, MIRM has a market cap of 6.4B. Regarding current trading prices, ALMS is priced at $29.27, while MIRM trades at $128.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas MIRM's P/E ratio is -9.43. In terms of profitability, ALMS's ROE is -0.55%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ALMS is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for ALMS.Check MIRM's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, LGND has a market cap of 6.4B. Regarding current trading prices, ALMS is priced at $29.27, while LGND trades at $319.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas LGND's P/E ratio is 38.30. In terms of profitability, ALMS's ROE is -0.55%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ALMS is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check LGND's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, ALMS is priced at $29.27, while BLTE trades at $157.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas BLTE's P/E ratio is -84.33. In terms of profitability, ALMS's ROE is -0.55%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, ALMS is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check BLTE's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ALMS is priced at $29.27, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ALMS's ROE is -0.55%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ALMS is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check CNTA's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, ALMS is priced at $29.27, while CGON trades at $69.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CGON's P/E ratio is -29.70. In terms of profitability, ALMS's ROE is -0.55%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ALMS is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check CGON's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CRSP has a market cap of 5.9B. Regarding current trading prices, ALMS is priced at $29.27, while CRSP trades at $60.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CRSP's P/E ratio is -11.89. In terms of profitability, ALMS's ROE is -0.55%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ALMS is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check CRSP's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ERAS has a market cap of 5.7B. Regarding current trading prices, ALMS is priced at $29.27, while ERAS trades at $18.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ERAS's P/E ratio is -41.73. In terms of profitability, ALMS's ROE is -0.55%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ALMS is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ERAS's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, SYRE has a market cap of 5.7B. Regarding current trading prices, ALMS is priced at $29.27, while SYRE trades at $94.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas SYRE's P/E ratio is -45.30. In terms of profitability, ALMS's ROE is -0.55%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ALMS is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for ALMS.Check SYRE's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CELC has a market cap of 5.6B. Regarding current trading prices, ALMS is priced at $29.27, while CELC trades at $115.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CELC's P/E ratio is -29.67. In terms of profitability, ALMS's ROE is -0.55%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ALMS is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check CELC's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ALMS is priced at $29.27, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ALMS's ROE is -0.55%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ALMS is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check CDTX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ALMS is priced at $29.27, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ALMS's ROE is -0.55%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ALMS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ABCM's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ALMS is priced at $29.27, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ALMS's ROE is -0.55%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ALMS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ISEE's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, TVTX has a market cap of 5.4B. Regarding current trading prices, ALMS is priced at $29.27, while TVTX trades at $57.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas TVTX's P/E ratio is -262.95. In terms of profitability, ALMS's ROE is -0.55%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ALMS is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check TVTX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ALMS is priced at $29.27, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas APLS's P/E ratio is 38.35. In terms of profitability, ALMS's ROE is -0.55%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ALMS is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check APLS's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, LEGN has a market cap of 5.1B. Regarding current trading prices, ALMS is priced at $29.27, while LEGN trades at $27.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas LEGN's P/E ratio is -40.71. In terms of profitability, ALMS's ROE is -0.55%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ALMS is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check LEGN's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, XENE has a market cap of 5B. Regarding current trading prices, ALMS is priced at $29.27, while XENE trades at $63.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas XENE's P/E ratio is -13.48. In terms of profitability, ALMS's ROE is -0.55%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ALMS is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check XENE's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CAI has a market cap of 4.9B. Regarding current trading prices, ALMS is priced at $29.27, while CAI trades at $17.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CAI's P/E ratio is -96.09. In terms of profitability, ALMS's ROE is -0.55%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ALMS is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for ALMS.Check CAI's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, VKTX has a market cap of 4.9B. Regarding current trading prices, ALMS is priced at $29.27, while VKTX trades at $42.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas VKTX's P/E ratio is -10.17. In terms of profitability, ALMS's ROE is -0.55%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ALMS is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALMS.Check VKTX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, ALMS is priced at $29.27, while MANE trades at $116.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas MANE's P/E ratio is -37.19. In terms of profitability, ALMS's ROE is -0.55%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ALMS is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check MANE's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, ALMS is priced at $29.27, while DFTX trades at $44.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas DFTX's P/E ratio is N/A. In terms of profitability, ALMS's ROE is -0.55%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ALMS is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check DFTX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ALMS is priced at $29.27, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas TERN's P/E ratio is -51.41. In terms of profitability, ALMS's ROE is -0.55%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ALMS is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check TERN's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, EWTX has a market cap of 4.6B. Regarding current trading prices, ALMS is priced at $29.27, while EWTX trades at $43.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas EWTX's P/E ratio is -25.98. In terms of profitability, ALMS's ROE is -0.55%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ALMS is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for ALMS.Check EWTX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ALMS is priced at $29.27, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ALMS's ROE is -0.55%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ALMS is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check FOLD's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ALMS is priced at $29.27, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ALMS's ROE is -0.55%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ALMS is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check AKRO's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, ALMS is priced at $29.27, while ACAD trades at $26.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ACAD's P/E ratio is 12.84. In terms of profitability, ALMS's ROE is -0.55%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ALMS is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ACAD's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ALMS is priced at $29.27, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ALMS's ROE is -0.55%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ALMS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check ALPN's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CRNX has a market cap of 4.4B. Regarding current trading prices, ALMS is priced at $29.27, while CRNX trades at $83.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CRNX's P/E ratio is -8.19. In terms of profitability, ALMS's ROE is -0.55%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ALMS is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check CRNX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, NAMSW has a market cap of 4.3B. Regarding current trading prices, ALMS is priced at $29.27, while NAMSW trades at $24.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas NAMSW's P/E ratio is -13.76. In terms of profitability, ALMS's ROE is -0.55%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ALMS is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check NAMSW's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, NAMS has a market cap of 4.3B. Regarding current trading prices, ALMS is priced at $29.27, while NAMS trades at $36.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas NAMS's P/E ratio is -23.26. In terms of profitability, ALMS's ROE is -0.55%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ALMS is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ALMS.Check NAMS's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ALMS is priced at $29.27, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas OPT's P/E ratio is -1.52. In terms of profitability, ALMS's ROE is -0.55%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ALMS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check OPT's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, DNLI has a market cap of 4.2B. Regarding current trading prices, ALMS is priced at $29.27, while DNLI trades at $26.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas DNLI's P/E ratio is -9.14. In terms of profitability, ALMS's ROE is -0.55%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ALMS is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check DNLI's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ALMS is priced at $29.27, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ALMS's ROE is -0.55%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ALMS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check MRTX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, DNTH has a market cap of 4B. Regarding current trading prices, ALMS is priced at $29.27, while DNTH trades at $95.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas DNTH's P/E ratio is -23.19. In terms of profitability, ALMS's ROE is -0.55%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ALMS is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check DNTH's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, ALMS is priced at $29.27, while TLX trades at $11.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas TLX's P/E ratio is -639.09. In terms of profitability, ALMS's ROE is -0.55%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ALMS is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check TLX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, ALMS is priced at $29.27, while DYN trades at $23.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas DYN's P/E ratio is -7.40. In terms of profitability, ALMS's ROE is -0.55%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ALMS is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check DYN's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, BEAM has a market cap of 3.9B. Regarding current trading prices, ALMS is priced at $29.27, while BEAM trades at $37.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas BEAM's P/E ratio is -12.19. In terms of profitability, ALMS's ROE is -0.55%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, ALMS is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for ALMS.Check BEAM's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ALMS is priced at $29.27, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas CPRX's P/E ratio is 11.33. In terms of profitability, ALMS's ROE is -0.55%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ALMS is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check CPRX's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, IDYA has a market cap of 3.9B. Regarding current trading prices, ALMS is priced at $29.27, while IDYA trades at $40.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas IDYA's P/E ratio is -25.32. In terms of profitability, ALMS's ROE is -0.55%, compared to IDYA's ROE of -0.14%. Regarding short-term risk, ALMS is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check IDYA's competition here

ALMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMS stands at 3.6B. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, ALMS is priced at $29.27, while TNGX trades at $30.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMS currently has a P/E ratio of -7.47, whereas TNGX's P/E ratio is -36.33. In terms of profitability, ALMS's ROE is -0.55%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, ALMS is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for ALMS.Check TNGX's competition here